On comparing type 1 versus type 2 diabetes, 61% of the type 2 cases tested positive as against 42% of the type 1 for MAU, indicating higher prevalence in NIDDM
cases, however, this association was not found to be statistically significant (p=0.
It was a prospective study undertaken to know the effect of IYT on blood sugar levels, glycosylated hemoglobin (HbA1c), and PFT parameters in 50 newly diagnosed patients of borderline NIDDM
In our study all IDDM patients were well controlled whereas patients with NIDDM
showed variable pattern of control of diabetes out of all 34 (63%) patients were well controlled however 20 (37%) patients had uncontrolled diabetes.
Role of insulin resistance in the pathogenesis of NIDDM
Therefore, it can be emphasized that the overall figures regarding the frequency of oral LP in NIDDM
Type 2 diabetes mellitus (formerly called NIDDM
, type II or adult-onset) is characterised by variable insulin resistance in peripheral tissue and insulin deficiency due to an insulin secretory defect of the beta cell.
Onset of NIDDM
occurs at least 4-7 years before clinical diagnosis.
The OLETF rats become spontaneously obese and NIDDM
with the hyperphagia expressed as a significant increase in the size of meals due to the lack of cholecystokinin-1 (CCK-1) receptors followed by development of hyperlipidemia, fatty liver, and diabetes (Kawano et al.
The mechanisms for NIDDM
have also undergone vigorous study over the past few years.
Bitter Melon (Momordica Charantia): Bitter melon, rumored to be on the hit list of the Codex Alimentarious and thus targeted for being banned, was demonstrated in one study to cause a hypoglycemic response when taken as an aqueous suspension in 86% of NIDDM
This approval is based on the results from the international clinical trial called RENAAL (Reduction of Endpoint in NIDDM
with A-II Antagonist Losartan), which covered 1,513 type-2 diabetics (including 96 Japanese patients).
The supporting data come from several clinical trials, including the Reduction of Endpoints in NIDDM
with the Angiotensin II Antagonist Losartan (RENAAL) study, as well as the Irbesartan Diabetic Nephropa thy Trial (IDNT).
: Clinical a not public health issue.
A multifaceted syndrome responsible for NIDDM
, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.
In the Reduction of End Points in NIDDM
with the Angiotensin II Antagonist Losartan (RENAAL) study, treatment with a RAS blocker halved proteinuria.